RecruitingPhase 3NCT06749899
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
Studying Nasopharyngeal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sun Yat-Sen University Cancer Center
- Principal Investigator
- Jun Ma, M.D.Sun Yat-sen University
- Intervention
- QL1706(drug)
- Enrollment
- 580 target
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2025 – 2030
Study locations (19)
- Fujian Cancer Hospital, Fuzhou, Fujian, China
- Dongguan People's Hospital, Dongguan, Guangdong, China
- First People's Hospital of Foshan, Foshan, Guangdong, China
- Guangzhou Panyu Central Hospital, Guangzhou, Guangdong, China
- Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
- Zhongshan People's Hospital, Zhongshan, Guangdong, China
- Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, China
- Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China
- Hubei Province Cancer Hosiptal, Wuhan, Hubei, China
- Renmin Hospital of Wuhan University, Wuhan, Hubei, China
- Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
- Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
- Hunan Cancer Hospital, Changsha, Hunan, China
- Xiangya Hospital of Central South University, Changsha, Hunan, China
- Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
- +4 more locations on ClinicalTrials.gov
Collaborators
Qilu Pharmaceutical Co., Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06749899 on ClinicalTrials.govOther trials for Nasopharyngeal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06980038Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07584499Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid TumorsSun Yat-sen University
- RECRUITINGPHASE2NCT07362979Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal CarcinomaSun Yat-sen University
- RECRUITINGPHASE3NCT07459296Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPCFirst Affiliated Hospital of Guangxi Medical University
- RECRUITINGNANCT06796270Hypofractionated Radiotherapy for Nasopharyngeal CarcinomaThe Second Affiliated Hospital of Hainan Medical University
- RECRUITINGPHASE2NCT06059261Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.Chongqing University Cancer Hospital
- RECRUITINGNCT07376603IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk FeaturesQiaojuan Guo
- RECRUITINGPHASE3NCT07340515Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III TrialMan Hu